Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Linaprazan Glurate Formulations and Food Effect
NCT05627518Phase 1Completed
- Sponsor
- Cinclus Pharma
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linaprazan glurate in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Cinclus Pharma. Primary endpoints: Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation (Ratio of AUCinf) at 72 hours, Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation (Ratio of AUClast) at 72 hours and 4 more. Started Nov 2022; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05627518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627518.